title: Expression profiling reveals alternative macrophage activation and impaired osteogenesis in periprosthetic osteolysis.
abstract: Interactions between periprosthetic cells and prosthetic wear debris have been recognized as an important event in the development of osteolysis and aseptic loosening. Although the ability of wear debris to activate pro-inflammatory macrophage signaling has been documented, the full repertoire of macrophage responses to wear particles has not been established. Here, we examined the involvement of alternative macrophage activation and defective osteogenic signaling in osteolysis. Using real-time RT-PCR analysis of periprosthetic soft tissue from osteolysis patients, we detected elevated levels of expression of alternative macrophage activation markers (CHIT1, CCL18), chemokines (IL8, MIP1 alpha) and markers of osteoclast precursor cell differentiation and multinucleation (Cathepsin K, TRAP, DC-STAMP) relative to osteoarthritis controls. The presence of cathepsin K positive multinuclear cells was confirmed by immunohistochemistry. Reduced expression levels of the osteogenic signaling components BMP4 and FGF18 were detected. Expression levels of TNF-alpha, IL-6, and RANKL were unchanged, while the anti-osteoclastogenic cytokine OPG was reduced in osteolysis patients, resulting in elevated RANKL:OPG ratios. In vitro studies confirmed the role of particulate debris in alternative macrophage activation and inhibition of osteogenic signaling. Taken together, these results suggest involvement in osteolysis of alternative macrophage activation, accompanied by elevated levels of various chemokines. Increased recruitment and maturation of osteoclast precursors is also observed, as is reduced osteogenesis. These findings provide new insights into the molecular pathogenesis of osteolysis, and identify new potential candidate markers for disease progression and therapeutic targeting.
authors.affiliation: Osteolysis Research Laboratory, Hospital for Special Surgery, 535 East 70th Street, New York, New York 10021, USA.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Koulouvaris
authors.forename: Khanh
authors.initials: K
authors.lastname: Ly
authors.forename: Lionel B
authors.initials: LB
authors.lastname: Ivashkiv
authors.forename: Mathias P
authors.initials: MP
authors.lastname: Bostrom
authors.forename: Bryan J
authors.initials: BJ
authors.lastname: Nestor
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Sculco
authors.forename: P Edward
authors.initials: PE
authors.lastname: Purdue
mesh_terms: D000077:Acetabulum / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019644:Arthroplasty, Replacement, Hip; D002478:Cells, Cultured; D016207:Cytokines / Q000235:genetics; D005260:Female; D005269:Femur / Q000601:surgery; D020869:Gene Expression Profiling; D006801:Humans; D008264:Macrophages / Q000502:physiology; D008297:Male; D008875:Middle Aged; D015207:Osteoarthritis, Hip / Q000601:surgery*; D010010:Osteoclasts / Q000502:physiology; D010012:Osteogenesis / Q000235:genetics* / Q000276:immunology; D010014:Osteolysis / Q000235:genetics* / Q000276:immunology; D019904:Polymethyl Methacrylate / Q000494:pharmacology; D011475:Prosthesis Failure; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013583:Synovial Membrane / Q000166:cytology / Q000187:drug effects; D014025:Titanium / Q000494:pharmacology
chemical_list: D016207:Cytokines; D019904:Polymethyl Methacrylate; D014025:Titanium